RALEIGH, N.C., March 7, 2013 (GLOBE NEWSWIRE) -- LipoScience, Inc. (Nasdaq:LPDX) today announced that Richard Brajer, President and Chief Executive Officer, and Lucy Martindale, Executive Vice President and Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 4:45 P.M. ET on Tuesday, March 12, 2013, in Miami, FL.
The presentation will be webcast live and can be accessed on the Investor Relations section of the corporate website at http://investor.liposcience.com. For those who are not available to listen to the live broadcast, the webcast will be archived for 90 days.
About LipoScience, Inc.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera, has been cleared by the FDA. It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk away automation. The Vantera® system will be placed with national and regional clinical laboratories.
LipoScience is driving toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.